Table 1.

Patient characteristics

Patient characteristics	Value
Age
Median (range)   Age ≥ 65 years, n (%)	71 (48–88) 49 (74.2)
PSA (ng/mL)
Median (range)	145 (7–9579)
ALP (U/L)
Median (range)	112 (35–1753)
Hemoglobin (g/dL)
Median (range)    < 13 g/dL, n (%)	12 (6–16) 44 (66.7)
ECOG performance status, n (%)
0   1    ≥ 2	17 (25.8) 31 (47.0) 18 (27.3)
Sites of metastases, n (%)
Bone   Lymph node   Liver   Other	62 (93.9) 49 (74.2) 12 (18.2) 16 (24.2)
Prior therapies, n (%)
Prostatectomy   Radiation   ADT   NAAD     Abiraterone     Enzalutamide     Abiraterone and enzalutamide   Chemotherapy     Docetaxel     Cabazitaxel     Docetaxel and cabazitaxel   [223Ra]Ra-dichloride   Other	32 (48.5) 41 (62.1) 66 (100) 65 (98.5) 50 (75.8) 54 (81.8) 39 (59.1) 47 (71.2) 46 (69.7) 21 (31.8) 20 (30.3) 14 (21.2) 11 (16.7)

PSA, prostate-specific antigen; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; ADT, androgen deprivation therapy; NAAD, novel androgen axis drugs